Cargando…

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy

Detalles Bibliográficos
Autores principales:	Wei, Jia, Mao, Zekai, Wang, Na, Huang, Lifang, Cao, Yang, Sun, Weimin, Long, Xiaolu, Tan, Jiaqi, Li, Chunrui, Xiao, Yi, Gu, Chaojiang, Zhang, Shangkun, Zhang, Yicheng, Zhang, Tongcun, Zhou, Jianfeng, Huang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507504/ https://www.ncbi.nlm.nih.gov/pubmed/32997409 http://dx.doi.org/10.1002/ctm2.176

Ejemplares similares

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
por: Wei, Jia, et al.
Publicado: (2022)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
por: Wang, Di, et al.
Publicado: (2021)

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

Antitumor Effects of Poplar Propolis on DLBCL SU-DHL-2 Cells
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

Validation of the diabetes, hypertension and hyperlipidemia (DHL) knowledge instrument in Malaysia
por: Lai, Pauline SM, et al.
Publicado: (2012)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Extracellular vesicles from dHL-60 cells as delivery vehicles for diverse therapeutics
por: Kim, Jun-Kyu, et al.
Publicado: (2021)

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model
por: Zhu, Zejiang, et al.
Publicado: (2022)

ATP-dependent DNA helicase (TaDHL), a Novel Reduced-Height (Rht) Gene in Wheat
por: Guo, Baojin, et al.
Publicado: (2022)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
por: Chen, Liting, et al.
Publicado: (2020)

TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy
por: Chen, Liting, et al.
Publicado: (2021)

Bidirectional best hit r-window gene clusters
por: Zhang, Melvin, et al.
Publicado: (2010)

Data on cytotoxicity in HeLa and SU-DHL-4 cells exposed to DPB162-AE compound
por: Bittremieux, Mart, et al.
Publicado: (2017)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

Comportamiento de las enzimas CK, GOT y DHL en pacientes con infarto de miocardio
por: Alcolea Figueroa, María Elena
Publicado: (1987)

Manuka Honey Modulates the Inflammatory Behavior of a dHL-60 Neutrophil Model under the Cytotoxic Limit
por: Minden-Birkenmaier, Benjamin A., et al.
Publicado: (2019)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
por: Zhang, Qi, et al.
Publicado: (2023)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

The Effect of Manuka Honey on dHL-60 Cytokine, Chemokine, and Matrix-Degrading Enzyme Release under Inflammatory Conditions
por: Minden-Birkenmaier, Benjamin A., et al.
Publicado: (2019)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

S261: FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Dickinson, Michael, et al.
Publicado: (2023)

Validating the Digital Health Literacy Instrument in Relation to COVID-19 Information (COVID-DHL-K) among South Korean Undergraduates
por: Chun, Heeran, et al.
Publicado: (2022)

Índice DHL-neutrófilos-linfocitos como predictor de mortalidad a 28 días en pacientes con COVID-19
por: Rojas-Sahagún, Víctor Manuel, et al.
Publicado: (2023)

miR-888: Hit it when you see it!
por: Bader, Andreas G
Publicado: (2014)

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
por: Lu, Yu, et al.
Publicado: (2022)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34
por: Huang, Zekai, et al.
Publicado: (2023)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
por: Wang, Di, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5gt5bakprldmecoe5k7cfl6tt6